Chief Executive Officer, Director and Founder
Dr. Coulter has built a reputation for innovation and leadership since founding Sigmoid in 2003, and developing its lead technology and products. Prior to Sigmoid, Dr. Coulter set up, developed and managed the drug formulation and diagnostics groups at NTera, a nanotechnology-focused company. Dr. Coulter has an honours degree and PhD in Pharmacology from University College Dublin, held a Post-Doctoral Fellowship at the Institut Curie, Paris, holds a Diploma in Accounting and Finance awarded by the Association of Chartered and Certified Accountants (ACCA) and was awarded a Fulbright Scholarship to complete an MBA at Cornell University, New York. Dr. Coulter is a member of the Irish Research Council.
SmPill® is the main focus of Sigmoid’s current development work and underpins all product development programmes. CyCol®, Sigmoid’s lead clinical development program, which is advancing into Phase 3 trials for moderate to severe ulcerative colitis, was uniquely enabled using SmPill® drug delivery technology.